ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: nail psoriasis

Updates in Osteoarthritis: Research Provides Insights into Molecular Pathogenesis of OA

Vanessa Caceres  |  December 8, 2021

In the ACR Convergence 2021 session on Updates in OA, presenters discuss the debate over OA phenotypes vs. endotypes, as well as note that research conducted over the past 20 years yields a better understanding of the pathogenesis of OA.

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2021

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  December 7, 2021

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice

Mary Beth Nierengarten  |  December 2, 2021

Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2021AS Resource Centeraxial spondyloarthritis (SpA)PsApsoriatic arthritis

Psoriatic Arthritis Treatment Update

Mary Choy, PharmD, BCGP, FASHP  |  October 13, 2021

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Filed under:Clinical Criteria/GuidelinesConditionsDrug UpdatesPsoriatic Arthritis Tagged with:PsA Resource Centerpsoriatic arthritis

The Latest Psoriatic Arthritis Management Insights

Jason Liebowitz, MD, FACR  |  October 11, 2021

An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater…

Filed under:ConditionsPsoriatic Arthritis Tagged with:psoriatic arthritis

Georgia Bonney

Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

Larry Beresford  |  August 6, 2021

As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

Filed under:Legislation & AdvocacyPractice Support Tagged with:Advocacyprior authorization

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measurespsoriatic arthritis

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR  |  December 17, 2020

The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersPediatric ConditionsVasculitis Tagged with:ACR Convergence 2020liver diseasemeeting reportsOsteoporosisPediatricpregnancyVasculitis

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

Lara C. Pullen, PhD  |  May 18, 2020

Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…

Filed under:ConditionsPsoriatic Arthritis Tagged with:apremilastcDAPSAClinical Disease Activity in Psoriatic Arthritis (cDAPSA)PsApsoriatic arthritis

Hair dye being applied to a man’s beard.

Case Report: A 50-Year-Old Man Suffers Dye-Induced Arthritis

Hrudya Abraham, MD, Eric Warm, MD, FACP, & Avis Ware, MD  |  December 18, 2019

Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine…

Filed under:Conditions Tagged with:case reportenvironmental factorpara-phenylenediamine (PPD)

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences